Skip to main content
SpringerLink
Log in

New Anticoagulants for Stroke Prophylaxis in Atrial Fibrillation

Assessing the Impact on Medication Adherence

  • Review Article
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, is a potent risk factor for stroke and transient ischemic attack. Most patients with AF receive antithrombotic stroke prophylaxis, often in the form of a vitamin K antagonist, typically warfarin. Drug treatment with warfarin is associated with significant management issues, such as an unpredictable dose response necessitating dose adjustments, frequent laboratory monitoring, and multiple interactions with other medications, as well as foods. A new generation of novel anticoagulants has emerged that includes dabigatran etexilate, a direct thrombin inhibitor, and rivaroxaban and apixaban, both highly selective factor Xa inhibitors. These newer agents possess a highly predictable pharmacokinetic-pharmacodynamic relationship, allowing for fixed dosing and no necessity for routine laboratory monitoring; additionally these agents have minimal drug interactions. Dabigatran etexilate and apixaban are both twice-daily medications, whereas rivaroxaban is administered once daily for stroke prophylaxis. The impact of dosing frequency on medication adherence with these agents has not been prospectively evaluated; however, the frequency of dosing intervals has been shown to affect medication adherence, which in turn may influence patient outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I

Similar content being viewed by others

References

  1. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369–429

    Article  PubMed  Google Scholar 

  2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370–5

    Article  PubMed  CAS  Google Scholar 

  3. Jorgensen HS, Nakayama H, Reith J, et al. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke 1996; 27: 1765–9

    CAS  Google Scholar 

  4. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864–70

    Article  PubMed  CAS  Google Scholar 

  5. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010; 137: 263–72

    Article  PubMed  Google Scholar 

  6. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 99th edition. American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2 Suppl.): e531S–75S

    Article  PubMed  CAS  Google Scholar 

  7. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation — executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006; 48: 854–906

    Article  PubMed  Google Scholar 

  8. Pradaxa [package insert]. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals, Inc; 2011

  9. Xarelto [package insert]. Titusville (NJ): Janssen Pharmaceuticals, Inc; 2011

  10. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981–92

    Article  PubMed  CAS  Google Scholar 

  11. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449–57

    Google Scholar 

  12. The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators. Arch Intern Med 1997; 157: 1237–40

    Google Scholar 

  13. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002; 288: 2441–8

    Article  PubMed  Google Scholar 

  14. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2011; 57: 1330–7

    Article  PubMed  Google Scholar 

  15. BayNews. FDA approves Xarelto® (rivaroxaban tablets) for the prophylaxis of deep vein thrombosis which may lead to a pulmonary embolism in patients undergoing knee or hip replacement surgery [online]. Available from URL: http://www.press.bayer.com/baynews/baynews.nsf/ID/2011-0333-e [Accessed 2011 Nov20]

  16. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.). Chest 2008; 133: 160S–98S

    Article  PubMed  CAS  Google Scholar 

  17. Coumadin [package insert]. Princeton (NJ): Bristol-Myers Squibb; 2010

  18. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoa Gulation with factor x. A next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010; 160: 635–41

    PubMed  CAS  Google Scholar 

  19. ELIQUIS [summary of product characteristics]. Middlesex: Bristol-Myers Squibb/Pfizer; 2011

  20. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–91

    Article  PubMed  CAS  Google Scholar 

  21. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–51

    Article  PubMed  CAS  Google Scholar 

  22. Connolly SJ, Ezekowitz MD, Yusuf S, et al., for the Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial [letter]. N Engl J Med 2010; 363 (19): 1875–6

    Article  PubMed  CAS  Google Scholar 

  23. Mega JL. A new era for anticoagulation in atrial fibrillation. N Engl J Med 2011; 365: 1052–4

    Article  PubMed  CAS  Google Scholar 

  24. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806–17

    Article  PubMed  CAS  Google Scholar 

  25. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor. Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116–27

    Google Scholar 

  26. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573–9

    Article  PubMed  CAS  Google Scholar 

  27. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012; 366 (9): 864–6. Letter

    Article  PubMed  CAS  Google Scholar 

  28. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 489–97

    Article  Google Scholar 

  29. Saini SD, Schoenfeld P, Kaulback K, et al. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009; 15: e22–33

    PubMed  Google Scholar 

  30. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296–310

    Article  PubMed  CAS  Google Scholar 

  31. Bae JP, Dobesh PP, Klepser DG, et al. Adherence and dosing frequency of common medications for cardiovascular patients. Am J Manag Care 2012; 18: 139–46

    PubMed  Google Scholar 

Download references

Acknowledgments

The author would like to acknowledge Matthew Romo, PharmD, for providing editorial support with funding from Janssen Scientific Affairs, LLC.

Author information

Authors and Affiliations

  1. Mayo Clinic, Rochester, 200 First Street SW, Rochester, Minnesota, MN 55905, USA

    Stephen Kopecky MD

Authors
  1. Stephen Kopecky MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen Kopecky MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kopecky, S. New Anticoagulants for Stroke Prophylaxis in Atrial Fibrillation. Am J Cardiovasc Drugs 12, 287–294 (2012). https://doi.org/10.1007/BF03261837

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03261837

Keywords

Search

Navigation